Exeliom Biosciences

Exeliom Biosciences is a developer of immunotherapies that harness the therapeutic potential of the gut microbiome. The company develops single bacterial strain candidates to deliver microbiome-based immunotherapies for treating inflammatory bowel disease and cancer, with Crohn's disease as the first indication, enabling patients to live longer and healthier lives by accessing medicines derived from the microbiome.